Volume 74, Issue 3, Pages (September 2018)

Slides:



Advertisements
Similar presentations
Volume 60, Issue 4, Pages (October 2011)
Advertisements

The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis  Maria I. Carlo, Darren R.
Volume 58, Issue 4, Pages (October 2010)
Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer  Marisa Warmuth,
Volume 53, Issue 4, Pages (April 2008)
Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum  John M. Fitzpatrick, Marc.
Volume 51, Issue 1, Pages (January 2007)
Volume 52, Issue 3, Pages (September 2007)
Volume 51, Issue 4, Pages (April 2007)
Volume 69, Issue 1, Pages 4-6 (January 2016)
Volume 74, Issue 2, Pages (August 2018)
Volume 68, Issue 1, Pages (July 2015)
Prostate Cancer Epidemic in Sight?
Volume 73, Issue 4, Pages e116-e118 (April 2018)
Volume 50, Issue 5, Pages (November 2006)
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Volume 66, Issue 2, Pages (August 2014)
The Global Risk of Bladder Cancer: Let's Just Do Something About It!
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 54, Issue 4, Pages (October 2008)
Elizabeth K. Bancroft, Rosalind A. Eeles
Volume 52, Issue 5, Pages (November 2007)
Volume 68, Issue 1, Pages 5-7 (July 2015)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Volume 70, Issue 3, Pages (September 2016)
Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
Volume 66, Issue 5, Pages (November 2014)
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 63, Issue 5, Pages (May 2013)
Volume 60, Issue 5, Pages (November 2011)
International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia  Brett Delahunt, John R. Srigley, Lars Egevad,
Laurent Boccon-Gibod  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
James N. Armitage, Stuart O. Irving, Neil A. Burgess  European Urology 
The PSA Era is not Over for Prostate Cancer
Volume 50, Issue 3, Pages (September 2006)
Volume 61, Issue 6, Pages (June 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 53, Issue 6, Pages (June 2008)
Volume 66, Issue 6, Pages (December 2014)
Leonard S. Marks, Jiaoti Huang  European Urology 
Volume 53, Issue 4, Pages (April 2008)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Volume 59, Issue 1, Pages (January 2011)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Volume 62, Issue 3, Pages (September 2012)
Volume 50, Issue 5, Pages (November 2006)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 73, Issue 4, Pages e116-e118 (April 2018)
Testicular Cancer Variations in Time and Space in Europe
Volume 53, Issue 1, Pages (January 2008)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Sergio Bracarda  European Urology Supplements 
European Urology is “Your” Journal
Volume 130, Issue 6, (September 2007)
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Economic Burden of Bladder Cancer Across the European Union
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Annika Berntsen, Poul F. Geertsen, Inge Marie Svane  European Urology 
Joaquim Bellmunt  European Urology Supplements 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Jan Roigas  European Urology Supplements 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Volume 134, Issue 6, (September 2008)
Presentation transcript:

Volume 74, Issue 3, Pages 387-393 (September 2018) Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis  Shreyas S. Joshi, Elizabeth A. Handorf, Matthew Zibelman, Elizabeth R. Plimack, Robert G. Uzzo, Alexander Kutikov, Marc C. Smaldone, Daniel M. Geynisman  European Urology  Volume 74, Issue 3, Pages 387-393 (September 2018) DOI: 10.1016/j.eururo.2018.05.025 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Study cohort eligibility CONSORT diagram and cohort criteria. NCDB=National Cancer Database; RCC=renal cell carcinoma. European Urology 2018 74, 387-393DOI: (10.1016/j.eururo.2018.05.025) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Adjusted 1-yr survival by facility volume. European Urology 2018 74, 387-393DOI: (10.1016/j.eururo.2018.05.025) Copyright © 2018 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.